Cost-effectiveness analysis of flucytosine as induction therapy in the treatment of cryptococcal meningitis in HIV-infected adults in South Africa
Abstract Background Cryptococcal meningitis in HIV-infected patients in sub-Saharan Africa accounts for three-quarters of the global cases and 135,000 deaths per annum. Current treatment includes the use of fluconazole and amphotericin B. Recent evidence has shown that the synergistic use of flucyto...
Saved in:
Main Authors: | Jacqui Miot (Author), Trudy Leong (Author), Simbarashe Takuva (Author), Andrew Parrish (Author), Halima Dawood (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2021-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prevalence and Hospital Management of Amphotericin B Deoxycholate-Related Toxicities during Treatment of HIV-Associated Cryptococcal Meningitis in South Africa.
by: Susan Meiring, et al.
Published: (2016) -
Bioavailability of a novel sustained‐release pellet formulation of 5‐flucytosine in healthy‐fed participants for use in patients with cryptococcal meningitis
by: Nabila Ibnou Zekri Lassout, et al.
Published: (2024) -
Management of cryptococcal meningitis in adults at Mthatha Hospital Complex, Eastern Cape, South Africa
by: Olufunso Oladipupo Sogbanmu, et al.
Published: (2014) -
Cryptococcal meningitis in a diabetic
by: Jyoti Prakash, et al.
Published: (2024) -
Cryptococcal meningitis: A neglected NTD?
by: Síle F Molloy, et al.
Published: (2017)